What does PHARMA-SEILLES do?

PHARMA-SEILLES is a pharmacy in Andenne. Private Limited, started on 6 October 1998, 1 establishment.

What is the address of PHARMA-SEILLES?

The registered office of PHARMA-SEILLES is located at Place Joseph Wauters 9, 5300 Andenne.

Is PHARMA-SEILLES still active?

Yes. According to the CBE (30 October 2026) PHARMA-SEILLES is active, legal situation “Normale toestand”, started on 6 October 1998.

Is PHARMA-SEILLES registered on Peppol?

Yes, PHARMA-SEILLES is registered on the Peppol network with ID 0208:0464296438.

What is the enterprise number of PHARMA-SEILLES?

The enterprise number of PHARMA-SEILLES is BE0464296438.

When was PHARMA-SEILLES founded?

PHARMA-SEILLES was founded on 6 October 1998.

Who are the directors of PHARMA-SEILLES?

According to the 2025 annual accounts, the directors of PHARMA-SEILLES are: HUBERT-DEBARSY SRL, José Hubert.

Is PHARMA-SEILLES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 October 1998; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMA-SEILLES make in 2025?

PHARMA-SEILLES posted a profit after taxes of € 79,596 in financial year 2025.

What is the revenue of PHARMA-SEILLES?

As a small company, PHARMA-SEILLES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 167,948.

How much does an employee at PHARMA-SEILLES earn?

The average wage cost per full-time employee at PHARMA-SEILLES was € 44,200 in 2022: staff costs of € 44,200 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA-SEILLES have?

According to the 2025 annual accounts, PHARMA-SEILLES has 0.6 full-time equivalents (FTE).

PHARMA-SEILLES (Private Limited) - Andenne - BE0464296438

Dossier PHARMA-SEILLES, printed on 30 October 2026 from databakkes.be/en/0464296438/pharma-seilles. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMA-SEILLES from Andenne, company number BE0464296438, closed financial year 2025 with a result of € 79,596 after tax. For that financial year PHARMA-SEILLES recorded a gross margin of € 167,948 and equity of € 81,412. Compared with financial year 2024, the result moved from € 79,350 to € 79,596. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on May 26, 2026.

What it is worth Healthy

€ 81,412

▼ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 79,596

Profit after tax over the fiscal year.

Cash in the bank

€ 30,559

▲ 34% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 90,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost

€ 55,074

▲ 6% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 8,484

▲ 79% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 25,000

▲ 112% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 69,133

▼ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 18,403

▼ 9% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 137,661 Gross margin 2022: € 137,661 First fiscal year in the series	€ 151,759 Gross margin 2023: € 151,759 ▲ 10% vs 2022 (€ 137,661) Favourable step	€ 162,102 Gross margin 2024: € 162,102 ▲ 7% vs 2023 (€ 151,759) Favourable step	€ 167,948 Gross margin 2025: € 167,948 ▲ 4% vs 2024 (€ 162,102) Favourable step	▲ 4%
Profit after taxes	€ 66,100 Profit after taxes 2022: € 66,100 First fiscal year in the series	€ 70,567 Profit after taxes 2023: € 70,567 ▲ 7% vs 2022 (€ 66,100) Favourable step	€ 79,350 Profit after taxes 2024: € 79,350 ▲ 12% vs 2023 (€ 70,567) Favourable step	€ 79,596 Profit after taxes 2025: € 79,596 Unchanged (€ 79,350) Favourable step
Equity	€ 141,899 Equity 2022: € 141,899 First fiscal year in the series	€ 112,466 Equity 2023: € 112,466 ▼ 21% vs 2022 (€ 141,899) Unfavourable step	€ 91,816 Equity 2024: € 91,816 ▼ 18% vs 2023 (€ 112,466) Unfavourable step	€ 81,412 Equity 2025: € 81,412 ▼ 11% vs 2024 (€ 91,816) Unfavourable step	▼ 11%
Total debts	€ 142,738 Total debts 2022: € 142,738 First fiscal year in the series	€ 194,461 Total debts 2023: € 194,461 ▲ 36% vs 2022 (€ 142,738) Unfavourable step	€ 202,561 Total debts 2024: € 202,561 ▲ 4% vs 2023 (€ 194,461) Unfavourable step	€ 202,536 Total debts 2025: € 202,536 Unchanged (€ 202,561) Favourable step
Cash	€ 27,734 Cash 2022: € 27,734 First fiscal year in the series	€ 26,702 Cash 2023: € 26,702 ▼ 4% vs 2022 (€ 27,734) Unfavourable step	€ 22,867 Cash 2024: € 22,867 ▼ 14% vs 2023 (€ 26,702) Unfavourable step	€ 30,559 Cash 2025: € 30,559 ▲ 34% vs 2024 (€ 22,867) Favourable step	▲ 34%
Retained profit	€ 123,149 Retained profit 2022: € 123,149 First fiscal year in the series	€ 93,716 Retained profit 2023: € 93,716 ▼ 24% vs 2022 (€ 123,149) Unfavourable step	€ 73,066 Retained profit 2024: € 73,066 ▼ 22% vs 2023 (€ 93,716) Unfavourable step	€ 62,662 Retained profit 2025: € 62,662 ▼ 14% vs 2024 (€ 73,066) Unfavourable step	▼ 14%
Dividend	€ 50,000 Dividend 2022: € 50,000 First fiscal year in the series	€ 100,000 Dividend 2023: € 100,000 ▲ 100% vs 2022 (€ 50,000) Unchanged	€ 100,000 Dividend 2024: € 100,000 Unchanged (€ 100,000) Unchanged	€ 90,000 Dividend 2025: € 90,000 ▼ 10% vs 2024 (€ 100,000) Unchanged	▼ 10%
Bank debt	€ 11,730 Bank debt 2022: € 11,730 First fiscal year in the series	€ 11,785 Bank debt 2023: € 11,785 Unchanged (€ 11,730) Unfavourable step	€ 11,782 Bank debt 2024: € 11,782 Unchanged (€ 11,785) Favourable step	€ 25,000 Bank debt 2025: € 25,000 ▲ 112% vs 2024 (€ 11,782) Unfavourable step	▲ 112%
Balance sheet total	€ 284,637 Balance sheet total 2022: € 284,637 First fiscal year in the series	€ 306,928 Balance sheet total 2023: € 306,928 ▲ 8% vs 2022 (€ 284,637) Unchanged	€ 294,377 Balance sheet total 2024: € 294,377 ▼ 4% vs 2023 (€ 306,928) Unchanged	€ 283,948 Balance sheet total 2025: € 283,948 ▼ 4% vs 2024 (€ 294,377) Unchanged	▼ 4%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	0.8 Employees (FTE) 2023: 0.8 ▼ 0.2 vs 2022 (1) Unchanged	0.6 Employees (FTE) 2024: 0.6 ▼ 0.2 vs 2023 (0.8) Unchanged	0.6 Employees (FTE) 2025: 0.6 Unchanged (0.6) Unchanged

Key figures of PHARMA-SEILLES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA-SEILLES?

What happened at PHARMA-SEILLES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 26, 2026 New annual accounts for financial year 2025: profit of € 79,596. Source: NBB ↗
Nov 25, 1998 New establishment in Andenne. KBO
Oct 6, 1998 Start of the company according to the CBE. KBO

In short

From € 66,100 profit in 2022 to € 79,596 profit in 2025.

Paid € 103,934 in corporate taxes since 2022.

Best year ever: 2025, with € 79,596 profit.

On average € 137,700 of value added per employee in 2022.

Original PDFs at the National Bank ↗

Management

HUBERT-DEBARSY 100%

The stake of HUBERT-DEBARSY comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA-SEILLES

Behind PHARMA-SEILLES are HUBERT-DEBARSY SRL and José Hubert. The shares are held by HUBERT-DEBARSY (100%).

Directors

According to the 2025 annual accounts

HUBERT-DEBARSY SRL

Director · represented by Marie Debarsy

José Hubert

Director

Also active at: HUBERT-DEBARSY

Shareholders

HUBERT-DEBARSY

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Place Joseph Wauters 9

5300 Andenne

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Association des Copropriétaires Résidence Les Oliviers à Seilles. place Joseph Wauters. 9

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0464.296.438

VAT number

BE 0464.296.438

Registered office

Place Joseph Wauters 9, 5300 Andenne

Names & denominations

PHARMA-SEILLES

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 October 1998

Peppol

Active · Active since 17 Jul 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA-SEILLES

Warning lights

Financials

What happened to PHARMA-SEILLES?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions